Marc Elia was named Chief Executive Officer of Invivyd, Inc., effective August 30, 2026. As of November 6, 2026, Invivyd, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 1, 2026, naming 5 appointments (Form 8-K, September 1, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Invivyd, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Marc Elia · Role: Chief Executive Officer · Effective: 2026-08-30 · 8-K, 2026-09-01
- · In / out: In · Person: Marc Elia · Role: Chief Financial Officer · 8-K, 2026-09-01
- · In / out: In · Person: Ajay Royan · Role: Lead Independent Director · 8-K, 2026-09-01
- · In / out: In · Person: Ajay Royan · 8-K, 2026-09-01
- · In / out: In · Person: Ian Sheffield · Role: Director · Effective: 2026-08-30 · 8-K, 2026-09-01
Invivyd, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-01. It names 3 people. Every row below is cited to the filing it comes from, and this page adds each new change as Invivyd, Inc. files it.
Also on the record for Invivyd, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 9.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Perceptive Advisors LLC | 6.3% of the class | 5%+ stakes | Source |
| July 28, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | — | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 7% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 9% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 6% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Maverick Capital, Ltd. | 6.7% of the class | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Soleus Capital Management, L.P. | 2.8% of the class | 5%+ stakes | Source |
| December 29, 2025 | Stake report, Schedule 13D/A, by Adimab, LLC | 7.3% of the class | 5%+ stakes | Source |
| November 25, 2025 | Stake report, Schedule 13G, by Perceptive Advisors LLC | 7.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Invivyd, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Invivyd, Inc. and the records around it.
Invivyd, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- M28 Capital Management LP also filed stake reports on 1 other company: CURIS INC (Jan 2026)
- Maverick Capital, Ltd. also filed stake reports on 5 other companies: Infleqtion, Inc. (May 2026), Peabody Energy Corporation (Feb 2026), Curis, Inc. (Nov 2025)
- Soleus Private Equity Fund III, L.P. also filed stake reports on 5 other companies: Prelude Therapeutics Inc (Jul 2026), CALCIMEDICA, INC. (May 2026), Aprea Therapeutics, Inc. (Apr 2026)
Watch Invivyd, Inc.
Get an email when Invivyd, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Invivyd, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Invivyd, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Invivyd, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 25 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-01 | In | Chief Executive Officer | 2026-08-30 | 8-K, 2026-09-01 | |
| 2026-09-01 | In | Chief Financial Officer | 8-K, 2026-09-01 | ||
| 2026-09-01 | In | Lead Independent Director | 8-K, 2026-09-01 | ||
| 2026-09-01 | In | 8-K, 2026-09-01 | |||
| 2026-09-01 | In | Director | 2026-08-30 | 8-K, 2026-09-01 |
Who leads Invivyd, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Lead Independent Director: Ajay Royan, appointed (filed 2026-09-01).
- Chief Financial Officer: Marc Elia, appointed (filed 2026-09-01).
- Director: Ian Sheffield, appointed, effective 2026-08-30 (filed 2026-09-01).
- Chief Executive Officer: Marc Elia, appointed, effective 2026-08-30 (filed 2026-09-01).
New leaders reset buying decisions — get the Full Report on Invivyd, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Invivyd, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Invivyd, Inc.Every change, in the filing's words
Appointed: Marc Elia, Chief Executive Officer, effective 2026-08-30
On August 30, 2026, the Board of Directors (the "Board") of Invivyd, Inc. (the "Company") appointed Marc Elia, Chairman of the Board, as the Company's Chief Executive Officer, effective as of August 30, 2026 (the "Effective Date").
Appointed: Marc Elia, Chief Financial Officer
Mr. Elia will serve as the Company's principal executive officer, a role previously held by William Duke, Jr., the Company's Chief Financial Officer, who remains the Company's principal financial officer and principal accounting officer.
Appointed: Ajay Royan, Lead Independent Director
In connection with the appointment of Mr. Elia as Chief Executive Officer, the Board appointed Ajay Royan as the Lead Independent Director of the Board, effective as of the Effective Date.
Appointed: Ajay Royan
The Board also appointed Mr. Royan to replace Mr. Elia as Chairperson of the Nominating and Corporate Governance Committee of the Board (the "Nominating and Corporate Governance Committee").
Appointed: Ian Sheffield, Director, effective 2026-08-30
On August 30, 2026, the Board, upon the recommendation of the Nominating and Corporate Governance Committee, increased the size of the Board from six directors to seven directors and appointed Ian Sheffield as a director to fill the resulting vacancy, effective as of August 30, 2026, with his term expiring at the Company's 2027 annual meeting of stockholders.
- Mr. Elia, age 50, has served as a member of the Board since June 2022 and as Chairman of the Board since July 2022.
- He previously served as a member of the Board from July 2020 to April 2021.
- Mr. Elia is the founder and chief investment officer of M28 Capital Management L.P., a healthcare sector investment fund, positions he has held since September 2019.
- Prior to that, from January 2012 to September 2019, Mr. Elia served as a partner at Bridger Capital, an investment fund.
- Mr. Elia currently serves on the board of directors of Fractyl Health, Inc., a publicly-traded metabolic therapeutics company.
- He previously served on the boards of directors of SQZ Biotechnologies Company and Adimab, LLC.
- Prior to his career in investing, Mr. Elia held various roles across the biotechnology industry at N30 Pharmaceuticals, Chiron Corporation, and L.E.K. Consulting.
- Mr. Elia holds a B.A. in Economics from Carleton College.
- In connection with Mr. Elia's appointment, the Company entered into an employment agreement with Mr. Elia (the "Employment Agreement").
- Pursuant to the Employment Agreement, Mr. Elia is entitled to receive an annual base salary of $750,000, which will be reviewed at least annually and will be subject to adjustment from time to time, as determined by the Board or the Compensation Committee of the Board (the "Compensation Committee").
Tools for this story
Each opens in a new tab, filled in for Invivyd, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.